cognitive cybersecurity intelligence

News and Analysis


Lexeo’s IPO Raises $100M for Gene Therapies That Treat the Heart, Protect the Brain

Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts